Hundreds of Institutional Investors to Attend Conference
LAS VEGAS, Sept. 10 /PRNewswire-FirstCall/ -- Skinvisible, Inc. (OTC Bulletin Board: SKVI / Website: http://www.skinvisible.com), the developers of Invisicare(R), a proprietary polymer delivery system for topically applied dermatology products, today announced that Mr. Terry Howlett, President & CEO, will present at the 4th annual Merriman Curhan Ford & Co. Investor Summit on September 18, 2007 at 2:15 PM. This event will be held at the Mark Hopkins InterContinental Hotel in San Francisco.
More information about the conference can be found at: http://www.merrimanco.com
About Merriman Curhan Ford & Co.
Merriman Curhan Ford & Co., a subsidiary of MCF Corporation (Amex: MEM), is an investment bank and securities broker-dealer focused on fast-growing companies and growth-oriented institutional investors. It provides investment research, brokerage and trading services primarily to institutions, as well as advisory and investment banking services to corporate clients. Its mission is to become a leader in the researching, advising, financing and trading of fast-growing companies. Merriman Curhan Ford & Co. is registered with the Securities and Exchange Commission as a broker-dealer and is a member of the National Association of Securities Dealers, Inc. and SIPC.
About Skinvisible Pharmaceuticals, Inc.
Skinvisible Pharmaceuticals, a wholly owned subsidiary of Skinvisible Inc., is a research-and-development company whose primary business objective is to license its proprietary formulations with Invisicare to pharmaceutical and cosmeceutical companies as well as assisting companies in revitalizing or enhancing their existing skin care products. Skinvisible receives a combination of research and development fees, upfront license fees, and ongoing royalties for the life of the patent. http://www.skinvisible.com
Invisicare is a patented polymer delivery system developed to hold active ingredients topically on the skin for extended periods of time. A key benefit is that Invisicare is non-occlusive on the skin, allowing normal skin respiration and perspiration. The Company has developed a portfolio of topical products using Invisicare for the dermatology and cosmeceutical industries. http://www.invisicare.com
This press release contains 'forward looking' statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10Q for the quarter ending June 30, 2007)
Terry Howlett, President/CEO
Skinvisible Pharmaceuticals, Inc
|SOURCE Skinvisible, Inc.|
Copyright©2007 PR Newswire.
All rights reserved